Uniphar PLC

Uniphar's capital structure is characterized by a debt-to-equity ratio of 1.27, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.99, suggesting that its current liabilities slightly exceed its current assets. Free cash flow for the period was EUR 18.94 million, which is significantly lower than the operating cash flow of EUR 108.43 million, primarily due to capital expenditures of EUR 62.82 million. In terms of profitability, Uniphar's return on equity (ROE) of 12.61% is relatively strong, but its return on assets (ROA) of 2.95% is below the typical industry benchmark for pharmaceutical companies. The company's gross profit of EUR 457.69 million and operating income of EUR 82.58 million indicate a narrow margin structure, which is common in the pharmaceutical distribution sector. Uniphar's revenue is primarily concentrated in the UK and Ireland, with no significant diversification across other geographic regions. The company does not disclose segment-specific revenue figures, but its business model is centered on pharmaceutical distribution, which is subject to regulatory and pricing pressures in its core markets. The company's growth trajectory is modest, with no specific revenue growth targets or projections provided in the available data. Analysts have assigned a mean price target of EUR 5.01, with a median of EUR 5.00, suggesting a neutral outlook on the stock. The absence of a clear growth strategy or expansion into new markets may limit Uniphar's long-term revenue potential. Uniphar faces several risk factors, including liquidity constraints due to a negative net cash position after accounting for total debt. The company's dilution risk is assessed as low, with no significant changes in shares outstanding between basic and diluted figures. However, the company's reliance on debt financing and the potential for regulatory changes in the pharmaceutical sector could impact its financial stability. Recent events, such as the company's financial performance and analyst estimates, suggest a stable but unremarkable outlook. No major corporate actions or strategic initiatives have been disclosed in the available data, and the company's financials do not indicate any significant recent changes in its business operations.